Loading patent…
AssigneeQ Therapeutics, Inc.
InventorsRobert Sandrock, James T. Campanelli, Deborah A. Eppstein
Estimating the term…
Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
A method for manufacturing mammalian glial restricted progenitor (GRP) cells, said method comprising:
A method for manufacturing mammalian glial restricted progenitor (GRP) cells, said method comprising:
A method for decreasing potentially unintended cellular phenotypes in a GRP cell population and/or decreasing standard deviations in cells of the GRP cell population, said method comprising:
A method for decreasing potentially unintended cellular phenotypes in a GRP cell population and/or decreasing standard deviations in cells of the GRP cell population, said method comprising:
A method for decreasing potentially unintended cellular phenotypes in a GRP cell population, said method comprising freezing and thawing the GRP cell population.
A method for manufacturing mammalian neural cells depleted of A2B5-positive cells, said method comprising:
An antibody panel for characterizing GRP cells comprising antibodies to A2B5, GFAP, and one or more antibodies selected from the group consisting of Olig1, Olig2, O1, PDGFR-α, nestin, NG2, PSA-NCAM, TuJ1, Ki-67 and NeuN.
Dependencies are inferred from the claim text.